Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:01:32 2026-06-29 pm EDT			After hours 08:00:00 pm
1,229.93 ^USD	+1.81%		1,229.00	-0.08%

01:59am	An exuberant quarter for equities, but not an irrational one?
01:36am	Innovent Biologics, Inc. and Eli Lilly and Company Enter Commercialization Agreement for Verzenios (Abemaciclib) in Mainland China	CI

Eli Lilly to Invest $4.5 Billion Across Two Indiana Manufacturing Sites

Published on 05/06/2026 at 09:35 am EDT

Dow Jones

ELI LILLY AND COMPANY

+1.81%

By Nicholas G. Miller

Eli Lilly will invest an additional $4.5 billion across two Indiana manufacturing sites.

The investment will incorporate new process designs and technologies at one of its active pharmaceutical ingredient sites, which is set to open in 2027, as well as a genetic medicine manufacturing facility that opens Wednesday.

Since 2020, Eli Lilly has committed more than $50 billion in U.S. capital expansion and more than $21 billion in Indiana manufacturing.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

05-06-26 0933ET

Latest news about Eli Lilly and Company

01:59am	An exuberant quarter for equities, but not an irrational one?
01:36am	Innovent Biologics, Inc. and Eli Lilly and Company Enter Commercialization Agreement for Verzenios (Abemaciclib) in Mainland China	CI
Jun. 29	Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program	MT
Jun. 29	Lilly, Regeneron selected for US program to review new manufacturing plants faster	RE
Jun. 29	FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports	RE
Jun. 29	Eli Lilly, Abu Dhabi's Health Department Enter MoU to Manage Obesity, Alzheimer's Disease	MT
Jun. 29	Emirati Shares End Lower as US-Iran Exchange Fresh Strikes	MT
Jun. 29	FDA set to review Sandoz's generic GLP-1s	RE
Jun. 29	Sandoz's Applications for Mounjaro, Zepbound Generics Accepted for FDA Review	DJ
Jun. 29	Sandoz New Drug Applications for Generic Tirzepatide Versions Accepted for US FDA Review	MT
Jun. 29	Pfizer, Innovent GLP-1 drugs clear China insurance hurdle	RE
Jun. 26	Health Care Up on Rotation Into Laggards -- Health Care Roundup	DJ
Jun. 26	Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy	CI
Jun. 26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
Jun. 26	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company